A Comparative Clinical Assessment of the Efficacy of Valacyclovir and Famciclovir in Herpes Zoster
- 1. PG-Student (3rd year), Department of Pharmacology, Darbhanga Medical College, Laheriasarai, Darbhanga, Bihar, India
- 2. Assistant Professor, Department of Pharmacology, Darbhanga Medical College, Laheriasarai, Darbhanga, Bihar, India
- 3. Associate Professor, Department of Pharmacology, Darbhanga Medical College, Laheriasarai, Darbhanga, Bihar, India
Description
Aim: The objective was to evaluate the efficacy of antiviral agent valacyclovir compared with famciclovir in the treatment of herpes zoster.
Methods: The present study is comprised of 100 patients who developed herpes zoster of both genders. All of the patients that were enrolled gave their consent. The ethical approval from the institutional ethical committee was done. The study was carried out at Department of Pharmacology, Darbhanga Medical College, Laheriasarai, Darbhanga, Bihar, India over a one-year period. Data such as name, age, gender, etc. was recorded. All were divided into 2 groups of 50 patients each. Group I patients were prescribed valacyclovir 1000 mg thrice daily, and Group II patients were prescribed famciclovir 500 mg thrice daily. The treatment was given for 7 days.
Results: The result showed that group I had 22 males and 20 females and group II had 18 males and 24 females. The result showed that dermatome in group I and group II involved were thoracic in 30 and 26, lumbar in 6 and 6, cervical in 8 and 10 and trigeminal in 6 and 8 respectively. The difference was non-significant (P> 0.05). The result showed the VAS scores comparison at every follow-up visit between both the groups. The mean VAS scores on the day of presentation, i.e., the baseline scores in both the groups were almost similar, and the difference was not statistically significant. The mean VAS scores in the valacyclovir group were significantly reduced at day 29 (P < 0.05) in comparison to the famciclovir group. Results showed a greater number of totally pain-free patients at day 30, i. e., 40 (80%) patients in the valacyclovir group, while in the famciclovir group, 30 (60%) patients were reported to be totally pain free, although it was statistically insignificant (P > 0.05). Conclusion: In comparison to famciclovir, oral valacyclovir administered for 7 days during acute zoster infection offers significant benefit by providing a well-tolerated and greater resolution of pain while maintaining a favourable safety profile, making valacyclovir more efficacious and a better drug in the management of Herpes Zoster.
Abstract (English)
Aim: The objective was to evaluate the efficacy of antiviral agent valacyclovir compared with famciclovir in the treatment of herpes zoster.
Methods: The present study is comprised of 100 patients who developed herpes zoster of both genders. All of the patients that were enrolled gave their consent. The ethical approval from the institutional ethical committee was done. The study was carried out at Department of Pharmacology, Darbhanga Medical College, Laheriasarai, Darbhanga, Bihar, India over a one-year period. Data such as name, age, gender, etc. was recorded. All were divided into 2 groups of 50 patients each. Group I patients were prescribed valacyclovir 1000 mg thrice daily, and Group II patients were prescribed famciclovir 500 mg thrice daily. The treatment was given for 7 days.
Results: The result showed that group I had 22 males and 20 females and group II had 18 males and 24 females. The result showed that dermatome in group I and group II involved were thoracic in 30 and 26, lumbar in 6 and 6, cervical in 8 and 10 and trigeminal in 6 and 8 respectively. The difference was non-significant (P> 0.05). The result showed the VAS scores comparison at every follow-up visit between both the groups. The mean VAS scores on the day of presentation, i.e., the baseline scores in both the groups were almost similar, and the difference was not statistically significant. The mean VAS scores in the valacyclovir group were significantly reduced at day 29 (P < 0.05) in comparison to the famciclovir group. Results showed a greater number of totally pain-free patients at day 30, i. e., 40 (80%) patients in the valacyclovir group, while in the famciclovir group, 30 (60%) patients were reported to be totally pain free, although it was statistically insignificant (P > 0.05). Conclusion: In comparison to famciclovir, oral valacyclovir administered for 7 days during acute zoster infection offers significant benefit by providing a well-tolerated and greater resolution of pain while maintaining a favourable safety profile, making valacyclovir more efficacious and a better drug in the management of Herpes Zoster.
Files
IJPCR,Vol15,Issue3,Article119.pdf
Files
(302.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8cb72d24aea7c94c80f76d9e0a1b9671
|
302.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-03-02
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue3,Article119.pdf
- Development Status
- Active
References
- 1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ open. 2014 Jun 1;4(6): e004833. 2. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? The Lancet infectious diseases. 2004 Jan 1;4(1): 26 -33. 3. Wareham DW, Breuer J. Herpes zoster. BMJ. 2007; 334:1211–5. 4. Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. The Korean journal of pain. 2015 Jul 1;28(3):177-84. 5. Glaser RB. Clinical aspects of herpes zoster. Western Journal of Medicine. 1983 Nov;139(5):718. 6. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents and Chemotherapy. 1995 Jul;39(7):1546- 53. 7. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? The Lancet infectious diseases. 2004 Jan 1;4(1) :26-33. 8. Glaser RB. Clinical aspects of herpes zoster. West J Med. 1983 Nov; 139 (5):718-20. 9. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul;39(7):1546-53. 10. Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T, Higuchi M, Inokuchi K, Jyo K, Koga H, Komai A, Maruta K, Mashiko T, Mihara T, Miyahara H, Miyasato M, Muto K, Nagase K, Nagata M, Sakihama H, Tanahashi T, Ueda A, Yamakawa K, Ohata C, Dainichi T, Tsuruta D, Hashimoto T. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol. 2012 Nov;39(11) :902-8. 11. Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F, Corey L. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006 Sep; 33(9):529-33.12. Schmader KE, Oxman MN. Varicella & Herpes zoster. In: Fitzpatrick's Dermatology in General Medicine. Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Pallar AS, Leffel DJ. 8thed, New York: McGraw- Hill; 2012 :2383-2401. 13. Suaya JA, Chen SY, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. In Open forum infectious diseases 2014 Sep 1 (Vol. 1, No. 2, p. ofu049). Oxford University Press. 14. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine. 2015 May 28; 37 2(22):2087-96. 15. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of clinical virology. 2010 May 1;48: S2-7. 16. Ansaldi F, Trucchi C, Alicino C, Paganino C, Orsi A, Icardi G. Realworld effectiveness and safety of a live-attenuated herpes zoster vaccine: a comprehensive review. Advances in Therapy. 2016 Jul; 33:1094-104. 17. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002; 66(9):1723-30. 18. Strauss SE, Oxman MN, Schmader KE. Varicella and herpes zoster. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: Mc Graw Hill Publishing Division; 2008. pp. 1885–98. 19. Araújo LQ, Macintyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes. 2007 Sep;14 Suppl 2:40-4. 20. Heininger U, Seward JF. Varicella. Lancet. 2006 Oct 14;368(9544):1365- 76. 21. Basic-Kes V, Demarin V. Postherpetic neuralgia. Acta Clinica Croatica. 2007 Sep 1;46(3):279-82. 22. Bist A, Savitha A, Gumma KM. Efficacy of valacyclovir and famciclovir in herpes zoster: A comparative study. Indian Journal of Pharmacology. 2020 Nov;52(6):472. 23. Indradevi R, Manoharan K, Oudeacoumar P, Karthikraja S, Jaffar NA. A comparative study to evaluate the efficacy and safety of valacyclovir and famcyclovir in the management of herpes zoster in a tertiary care hospital in Puducherry. Journal of Evolution of Medical and Dental Sciences. 2014 May 26;3(21):5804-13. 24. Kenfuni M. M., Gallouo M., Alafifi Mahmoud Tsikambu A. C. D., Alafifi R., Moataz A., Dakir M., Debbagh A., & Aboutaieb R. Pyonephrose: Risk factors, clinical, para-clinical and anatomopathological profile about 19 cases. Journal of Medical Research and Health Sciences, 2022; 5(2): 1770– 1773.